Overcoming barriers to migraine care with preventive treatment: The “beauty” of monoclonal antibodies
Despite the availability of preventive treatments for migraine, there are still unmet needs for patients and considerable barriers to optimal migraine treatment.1 As part of a symposium at the 7th Congress of the European Academy of Neurology, Prof. Uwe Reuter (Charité Universitätmedizin, Berlin, Germany), Prof. Peter Goadsby (King’s College, London, United Kingdom)
Login to register to read this article
If you do not have a Log in, please register to be part of a big community, experience premium content and stay informed about exclusive professional events.
Log InNot registered yet? Register now